rs2731672 — F12

Factor XII — The Hidden Coagulation Switch

Most coagulation variants are straightforward: a gene changes, clotting goes up or down. Factor XII defies that logic. The gene at the heart of the contact activation pathway¹¹ contact activation pathway
the intrinsic coagulation cascade triggered when blood contacts foreign surfaces or negatively charged molecules was long thought inconsequential in humans — people completely lacking Factor XII don't bleed abnormally. Yet elevated Factor XII levels turn out to be an independent cardiovascular risk factor, and recent large-scale genomic data confirm that genetically lower Factor XII is protective against thrombosis. The rs2731672 variant in the F12 locus is the most replicated genetic determinant of Factor XII activity levels, explaining more variance in the clotting test aPTT than almost any other common variant.

The Mechanism

rs2731672 sits at chr5:177,415,473 (GRCh38), approximately 7 kilobases downstream of the F12 gene. It is in strong linkage disequilibrium with rs1801020, the well-characterized F12 C46T variant in the 5'-untranslated region of the gene. The C46T change impairs translation efficiency of Factor XII protein — fewer ribosomes successfully initiate translation from the modified UTR, reducing secreted Factor XII levels. The rs2731672 T allele tags this low-expression haplotype, so carriers of TT have substantially lower circulating Factor XII than CC homozygotes.

Factor XII initiates the contact activation cascade by autoactivating on negatively charged surfaces (collagen, polyphosphates, nucleic acids released from activated platelets and dying cells). Activated Factor XII (FXIIa) then activates Factor XI, ultimately generating thrombin and a fibrin clot. Paradoxically, although complete FXII deficiency causes isolated prolonged aPTT with no bleeding tendency, elevated FXIIa correlates with heightened coagulation tone, higher fibrinopeptide A (a marker of active fibrin formation), and increased coronary disease risk.

Additionally, rs2731672 maps to the kallikrein-kinin system region alongside KLKB1 (plasma kallikrein). A GWAS of vasoactive peptide levels²² A GWAS of vasoactive peptide levels
Verweij et al., Hypertension 2013 identified strong epistatic interactions between rs2731672 and the KLKB1 variant rs4253238 for plasma levels of adrenomedullin and endothelin-1 precursors — two vasoregulatory peptides that independently predict cardiac death and heart failure — adding a vascular tone dimension to the FXII story.

The Evidence

The genetic architecture of Factor XII levels was established by a GWAS in two Scottish birth cohorts (n=1,477)³³ GWAS in two Scottish birth cohorts (n=1,477)
Houlihan et al., Am J Hum Genet 2010, which found rs2731672 to be the single most significant genetic determinant of aPTT (p=2.16×10⁻³⁰). Together with variants in KNG1 (high-molecular-weight kininogen) and HRG (histidine-rich glycoprotein), this three-SNP model explained approximately 18% of phenotypic variance in aPTT — a remarkably large fraction for complex trait GWAS, reflecting the strong genetic control over Factor XII expression.

The cardiovascular consequences of FXII activity levels were clarified in a prospective study of 2,624 middle-aged Scottish men⁴⁴ prospective study of 2,624 middle-aged Scottish men
Lowe et al., Circulation 2000, which measured plasma FXIIa (activated Factor XII) and followed men for coronary heart disease over several years. Men in the highest third of FXIIa concentration had a hazard ratio of 1.96 for CHD compared to the lowest third (P=0.007) — nearly a doubling of risk. Genotype strongly predicted FXIIa: CC carriers averaged 2.0 ng/mL, CT intermediate at 1.4 ng/mL, and TT the lowest at 0.8 ng/mL. Higher FXIIa also correlated with elevated fibrinopeptide A, confirming active coagulation cascade engagement in vivo.

The WOSCOPS statin trial (n=6,595 hypercholesterolaemic men)⁵⁵ WOSCOPS statin trial (n=6,595 hypercholesterolaemic men)
Koch et al., Atherosclerosis 2002 added a pharmacogenomic dimension: men with the high-FXII CC genotype showed significant cardiovascular benefit from pravastatin (OR 0.76 for CHD), while those with the low-FXII TT genotype did not benefit from statin therapy. This interaction suggests the FXIIa pathway and the LDL-mediated atherosclerotic pathway interact, and that lipid lowering is particularly valuable for individuals whose genotype sustains high contact activation tone.

The largest and most definitive evidence comes from a 2025 population-scale analysis in 703,745 participants⁶⁶ population-scale analysis in 703,745 participants
Lorentz et al., Nat Commun 2025 showing that heterozygous F12 loss-of-function variant carriers are protected against venous thromboembolism without any increased risk of bleeding complications or infection — validating Factor XII as a safe therapeutic target and confirming that lower FXII is genuinely protective.

Practical Actions

For CC homozygotes, the main implication is heightened thrombotic risk through the contact activation pathway. This is not a pathway addressed by standard anticoagulants (warfarin, DOACs), which target the tissue factor pathway. The most relevant management strategies involve monitoring classical cardiovascular risk biomarkers (aPTT, fibrinogen), addressing other thrombotic risk factors, and being aware of the potential for increased clotting risk with factors that activate the contact pathway (e.g., foreign surfaces during surgery, implanted devices, or severe inflammatory states).

For TT homozygotes — particularly common in East Asian populations — the genotype confers a natural reduction in coagulation tone that appears to be protective against both arterial and venous thrombotic events, with no apparent cost in terms of bleeding or infection risk.

Interactions

rs2731672 is in strong LD with rs1801020 (F12 5'-UTR C46T), the primary functional variant affecting Factor XII translation. These two SNPs essentially tag the same biological signal and should not be double-counted.

The epistatic relationship with rs4253238 in KLKB1 (plasma kallikrein, the immediate downstream activator of Factor XII in the contact pathway) is well-documented for vasoactive peptide levels. Carriers of low-activity haplotypes at both F12 and KLKB1 may have compounded reduction in contact activation and are candidates for the most favorable thrombosis-protective profile, while those with high-activity alleles at both loci may have the highest contact-pathway-mediated clotting risk.